Tulane Home Tulane Home
Subscribe to NIH Grants feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 18 hours 46 min ago

Programs for Inclusion and Diversity Among Individuals Engaged in Health-Related Research (PRIDE) Coordination Center (U24 Clinical Trial Not Allowed)

Tue, 01/10/2023 - 03:25
Funding Opportunity RFA-HL-24-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits a single five-year grant application from eligible institutions/organizations to serve as the Coordination Center (CC) for the Programs for Inclusion and Diversity Among Individuals Engaged in Health-Related Research (PRIDE) Summer Institutes (SIs). This FOA runs in parallel with a separate FOA that solicits applications for the PRIDE SIs (described in detail in RFA-HL-24-004). PRIDE SIs are designed to provide research education experiences that enable junior faculty and transitioning postdoctoral scientists from diverse backgrounds, including those from groups that who are underrepresented in the biomedical sciences (see NOT-OD-20-031) to further develop their research skills and knowledge to become competitive NIH grants applicants and scientists. The purpose of the CC is to provide programmatic support for the PRIDE program overall and to complement the activities of the SI programs.

Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)

Tue, 01/10/2023 - 03:19
Funding Opportunity PAR-23-073 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and protected time (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

Notice of Change to RFA-PM-23-001, Enhancing the Use of the All of Us Research Programs Data (R21 Clinical Trial Not Allowed);

Tue, 01/10/2023 - 03:06
Notice NOT-PM-23-004 from the NIH Guide for Grants and Contracts

NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)

Mon, 01/09/2023 - 11:39
Funding Opportunity PAR-23-071 from the NIH Guide for Grants and Contracts. The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (FOA #).

Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed)

Mon, 01/09/2023 - 09:53
Funding Opportunity RFA-OD-23-001 from the NIH Guide for Grants and Contracts. This FOA encourages grant applications for Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals, as well as other resources such as informatics tools, reagents, cultures (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The goal of projects supported by this FOA is to provide research resources that facilitate optimization and enhancement of scientific rigor, transparency, and experimental reproducibility of biomedical research. Proposed Animal and Biological Material Resource Centers must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIPs NIH-wide mission (https://orip.nih.gov/about-orip). This funding opportunity is designed to support both continuation of existing resources and to develop new ones when appropriate. Prior to preparing an application, all applicants are strongly encouraged to consult with Scientific/Research staff to be advised on appropriateness of the intended resource plans for this program, competitiveness of a potential application, and ORIP's program priorities.

Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)

Mon, 01/09/2023 - 03:06
Funding Opportunity PAR-22-261 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite R03 applications to support archiving and documenting existing data sets in order to enable secondary analysis of these data by the scientific community. The priority of this program is to archive data sets within the scientific mission of the NICHD; highest priority is to archive data collected with NICHD support.

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

Mon, 01/09/2023 - 02:51
Funding Opportunity RFA-NS-23-012 from the NIH Guide for Grants and Contracts. The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical trials for the diagnosis, mitigation, treatment, or cure of ALS ("intermediate EA protocol for ALS"). Providing the investigational drug or biological product under an intermediate EA protocol for ALS must not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval, or otherwise compromise the potential development of medical products for the diagnosis, mitigation, treatment, or cure of ALS. Eligible applicants are clinical trial sites that participate in a phase 3 clinical trial supported by a United States (U.S.) small business concern (as defined in section 3(a) of the Small Business Act (15 U.S. C. 623(a)) that is also the U.S. Food and Drug Administration (FDA) designated sponsor of a drug or biological product for ALS that is the subject of an Investigational New Drug Application (IND). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2022 with an expected application due date in June 2022. This FOA will utilize the U01 activity code.

Notice of Guidance for Data Management and Sharing Plans for the National Institute of Alcohol Abuse and Alcoholism (NIAAA)

Mon, 01/09/2023 - 00:55
Notice NOT-AA-23-001 from the NIH Guide for Grants and Contracts

Notice of Request for Proposals (RFP), Solicitation 75N91023R00024: PREVENT Cancer Preclinical Drug Development Program

Mon, 01/09/2023 - 00:54
Notice NOT-CA-23-034 from the NIH Guide for Grants and Contracts

Notice of Special Interest (NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases

Mon, 01/09/2023 - 00:51
Notice NOT-DA-22-048 from the NIH Guide for Grants and Contracts

NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)

Mon, 01/09/2023 - 00:42
Funding Opportunity PAR-23-070 from the NIH Guide for Grants and Contracts. The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (FOA #).

Laboratories to Optimize Digital Health (R01 Clinical Trial Required)

Fri, 01/06/2023 - 10:18
Funding Opportunity PAR-23-096 from the NIH Guide for Grants and Contracts. NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions. This FOA is intended to support the development of digital health test beds that leverage well-established digital mental health platforms,to rapidly refine and optimize existing evidence-based digital health interventions and conduct clinical trials testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness.

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)

Fri, 01/06/2023 - 09:51
Funding Opportunity PAR-23-088 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging findings in TBI-related dementia and/or VCID (U24 - Clinical Trials Not Allowed)

Fri, 01/06/2023 - 09:46
Funding Opportunity RFA-NS-23-002 from the NIH Guide for Grants and Contracts. The purpose of this Alzheimers Disease-Related Dementia (ADRD) initiative is to promote the development and distribution of innovative technologies, methods, protocols, and biomedical materials that enhance combined human neuropathology and neuroimaging research with data aimed at understanding the underlying pathophysiology of in vivo imaging results typically associated with vascular contributions to cognitive impairment and dementia (VCID) in TBI-related dementia and other ADRD diagnoses. Resources developed under this FOA must follow open data sharing practices and are intended to expand the broader research communitys capacity to perform research aimed at neuropathologically-informed understanding of the vascular pathophysiology of clinically-relevant, in vivo neuroimaging findings.

Pages